Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Chittoria, Namita; Haddad, Housam; Elson, Paul; Tannir, Nizar; Wood, Laura; Dreicer, Robert; Garcia, Jorge; Rini, Brian; Jonasch, Eric
• Is Part Of: BMC cancer. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 7
• Publication Date: 2016-12
• Subjects: Renal cell carcinoma -- Axitinib -- Sunitinib -- VEGF inhibitors -- mTOR inhibitors -- Predictive biomarkers; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2282-5
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patients progressing on axitinib is of interest. Methods Patients with advanced renal cell carcinoma of any pathologic subtype treated with at least one cycle (four weeks) of axitinib followed by at least one subsequent targeted therapy were investigated in a retrospective analysis. Patient characteristics, duration of treatment and clinical outcomes were analyzed for axitinib and each subsequent line of therapy by Response Evaluation Criteria in Solid Tumors (RECIST). Results Twenty-five mRCC patients who received at least one approved targeted agent following axitinib were identified. Eight percent of patients achieved a partial response (one patient each to sunitinib and pazopanib) and 42 % had a best response of stable disease to the first therapy after axitinib. The estimated median duration of therapy was 4.4 months (range, 0.2–27.5+). Twelve patients received a second post-axitinib targeted therapy. Six out of 11 evaluable patients (55 %) had a best response of SD. The estimated median duration of treatment was 4.8 months (range, 0.7–19.1+). Conclusion Objective responses and stable disease is observed to post-axitinib targeted therapies and prospective studies are needed for validating role of predictive biomarkers.